Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
Severe or critical COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
All‐cause mortality	N/A	N/A	N/A	N/A	N/A
Serious adverse events	3	229	Risk Ratio (M‐H, Random, 95% CI)	0.34 (0.01 to 8.17)	N/A
Systemic reactogenicity events	1	101	Risk Ratio (M‐H, Random, 95% CI)	1.96 (0.52 to 7.41)	N/A
Any adverse event	3	N/A	Risk Ratio (M‐H, Random, 95% CI) Not pooled	1.03 (0.75 to 1.43) 1.21 (0.87 to 1.68) 3.19 (1.11 to 9.11)	N/A
Local reactogenicity events	1	101	Risk Ratio (M‐H, Random, 95% CI)	11.76 (1.59 to 87.14)	N/A